Selling long life

4 min read Original article ↗
  • Feature
  • Published:

Nature Biotechnology volume 33pages 31–40 (2015)Cite this article

Subjects

An Erratum to this article was published on 12 May 2015

A Corrigendum to this article was published on 06 February 2015

This article has been updated

A new generation of commercial entities is beginning to explore opportunities for new types of interventions and services in a graying world.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$259.00 per year

only $21.58 per issue

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Going to extremes.

The alternative text for this image may have been generated using AI.

Figure 2: Increase in life expectancy at birth with elimination of disease.

The alternative text for this image may have been generated using AI.

Figure 3: Molecular targets for caloric restriction and interventions against premature aging.

The alternative text for this image may have been generated using AI.

Figure 4: The wellderly.

The alternative text for this image may have been generated using AI.

Alamy

Figure 5

The alternative text for this image may have been generated using AI.

Alamy

Change history

  • 14 January 2015

    In the version of this article initially published, the caption for Figure 5 read “Pope Innocent VIII, likely the first patient to undergo parabiosis.” In fact, he did not undergo parabiosis, but a blood transfusion. The caption should have read “Pope Innocent VIII died in a rejuvenation attempt in 1492.” The errors have been corrected in the HTML and PDF versions of the article.

  • 30 April 2015

    In the version of this article initially published, Retrotope Inc. was included in Table 1 in the “Walking dead” category. Nature Biotechnology has since been informed by Retrotope management that the company raised $10 million in seed funding in 2014. Retrotope has been removed from Table 1. The error has been corrected in the HTML and PDF versions of the article.

References

  1. Partridge, L. The new biology of ageing. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 365, 147–154 (2010).

    Article  Google Scholar 

  2. Olshansky, S.J., Carnes, B.A. & Cassel, C. In search of Methuselah: estimating the upper limits of human longevity. Science 250, 634–640 (1990).

    Article  CAS  Google Scholar 

  3. de Cabo, R. et al. The search for antiaging interventions: from elixirs to fasting regimes. Cell 157, 1515–1526 (2014).

    Article  CAS  Google Scholar 

  4. Kenyon, C., Chang, J., Gensch, E., Rudner, A. & Tabtiang, R. A C. elegans mutant that lives twice as long as wild type. Nature 366, 461–464 (1993).

    Article  CAS  Google Scholar 

  5. Garber, K., A midlife crisis for aging theory., Nat. Biotechnol., 26, 371–374 (2008).

    Article  CAS  Google Scholar 

  6. McCay, C.M. et al. The effect of retarded growth upon the length of life span and the ultimate body size. J. Nutr. 10, 63–79 (1935).

    Article  CAS  Google Scholar 

  7. Steakley, L. An experiment that “treats each person as his or her own experiment.” Scope http://scopeblog.stanford.edu/2014/02/12/an-experiment-that-treats-each-person-as-his-or-her-own-experiment/ (12 February 2014).

    Google Scholar 

  8. Britt, R.R. Infusion of young blood revives old muscles. livesciencehttp://www.livescience.com/156-infusion-young-blood-revives-muscles.html (16 February 2005).

  9. Rochon, J. et al. Design and conduct of the CALORIE study. J. Gerontol. A Biol. Sci. Med. Sci. 66A, 97–108 (2011).

    Article  Google Scholar 

  10. Stipp, D. The Youth Pill: Scientists at the Brink of an Anti-Aging Revolution (Current, New York, 2010).

    Google Scholar 

Download references

Author information

Author notes

  1. Christopher Thomas Scott and Laura DeFrancesco: Christopher Thomas Scott is a Contributing Editor at Nature Biotechnology

Authors and Affiliations

  1. Laura DeFrancesco is a Senior Editor at Nature Biotechnology.,

    Laura DeFrancesco

Authors

  1. Christopher Thomas Scott
  2. Laura DeFrancesco

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Scott, C., DeFrancesco, L. Selling long life. Nat Biotechnol 33, 31–40 (2015). https://doi.org/10.1038/nbt.3108

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt.3108